Free Trial

Organovo Q4 2024 Earnings Report

Organovo logo
$0.36 -0.01 (-3.28%)
(As of 12/20/2024 05:31 PM ET)

Organovo EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$50.00 thousand
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Q4 2024
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Organovo Earnings Headlines

Organovo Holdings Inc
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Organovo Holdings Gains Approval for Key Strategic Moves
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat

Upcoming Earnings